Niagen Bioscience, Inc. (NAGE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Niagen Bioscience, Inc. (NAGE) has a cash flow conversion efficiency ratio of 0.052x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($3.69 Million) by net assets ($70.68 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Niagen Bioscience, Inc. (NAGE) total market value for the company's overall valuation and market capitalisation.
Niagen Bioscience, Inc. - Cash Flow Conversion Efficiency Trend (2007–2024)
This chart illustrates how Niagen Bioscience, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Niagen Bioscience, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Niagen Bioscience, Inc. ranked by their cash flow conversion efficiency. Explore cash flow quality index of Niagen Bioscience, Inc. to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ICP DAS Co Ltd
TWO:3577
|
-0.003x |
|
Omaxe Limited
NSE:OMAXE
|
0.064x |
|
Shanghai Jin Jiang International Hotels Development Co Ltd B
SHG:900934
|
0.084x |
|
Acadian Timber Corp
TO:ADN
|
0.007x |
|
First Savings Financial Group Inc
NASDAQ:FSFG
|
0.544x |
|
Sichuan Dowell Science and Technology Inc
SHE:300535
|
0.004x |
|
Activate Energy Acquisition Corp. Class A Ordinary Share
NASDAQ:AEAQ
|
-0.001x |
|
Hansae Co
KO:105630
|
0.006x |
Annual Cash Flow Conversion Efficiency for Niagen Bioscience, Inc. (2007–2024)
The table below shows the annual cash flow conversion efficiency of Niagen Bioscience, Inc. from 2007 to 2024. View NAGE share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $46.09 Million | $12.11 Million | 0.263x | +5.04% |
| 2023-12-31 | $28.46 Million | $7.12 Million | 0.250x | +147.50% |
| 2022-12-31 | $28.67 Million | $-15.10 Million | -0.527x | +30.86% |
| 2021-12-31 | $31.73 Million | $-24.16 Million | -0.762x | -18.00% |
| 2020-12-31 | $16.42 Million | $-10.60 Million | -0.645x | +35.44% |
| 2019-12-31 | $20.45 Million | $-20.44 Million | -1.000x | -29.95% |
| 2018-12-31 | $27.18 Million | $-20.91 Million | -0.769x | -322.42% |
| 2017-12-31 | $53.83 Million | $-9.80 Million | -0.182x | +38.14% |
| 2016-12-31 | $9.97 Million | $-2.94 Million | -0.294x | +26.44% |
| 2015-12-31 | $5.27 Million | $-2.11 Million | -0.400x | +37.98% |
| 2014-12-31 | $4.00 Million | $-2.58 Million | -0.645x | +6.39% |
| 2013-12-31 | $5.67 Million | $-3.91 Million | -0.689x | +72.79% |
| 2012-12-31 | $3.99 Million | $-10.12 Million | -2.534x | -58.35% |
| 2011-12-31 | $2.56 Million | $-4.10 Million | -1.600x | -196.80% |
| 2010-12-31 | $4.94 Million | $-2.66 Million | -0.539x | -42.56% |
| 2009-12-31 | $1.05 Million | $-396.17K | -0.378x | +65.57% |
| 2008-12-31 | $1.75 Million | $-1.92 Million | -1.098x | +99.49% |
| 2007-12-31 | $180.00 | $-38.48K | -213.794x | -- |
About Niagen Bioscience, Inc.
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+)… Read more